Back to Search

DAVID EBERHARD, MD

MD

Anatomic Pathology Physician

NPI: 1497118608Individual

Specialties, Licenses & Credentials

Anatomic Pathology PhysicianPrimary

Pathology — Anatomic Pathology

Code: 207ZP0101X

2009-01833(NC)
General Practice Physician

General Practice

Code: 208D00000X

2009-01833(NC)

Research & Publications (20)

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
PMID 18281673·J Clin Oncol·2008
6-review
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
PMID 16043828·J Clin Oncol·2005
3-trial
Control of the nuclear-cytoplasmic partitioning of annexin II by a nuclear export signal and by p11 binding.
PMID 11590242·J Cell Sci·2001
7-preclinical
A tumor sorting protocol that enables enrichment of pancreatic adenocarcinoma cells and facilitation of genetic analyses.
PMID 19460940·J Mol Diagn·2009
8-other
Robust and sensitive iTRAQ quantification on an LTQ Orbitrap mass spectrometer.
PMID 18511480·Mol Cell Proteomics·2008
8-other
The western corn rootworm (Diabrotica virgifera virgifera) and its first appearance in Germany 2007.
PMID 19226788·Commun Agric Appl Biol Sci·2008
7-preclinical
Transdifferentiation and metaplasia as a paradigm for understanding development and disease.
PMID 18030422·Cell Mol Life Sci·2008
6-review
Origin of pancreatic endocrine cells from biliary duct epithelium.
PMID 18810318·Cell Mol Life Sci·2008
7-preclinical
Origin of beta-cells in regenerating pancreas.
PMID 18536025·Bioessays·2008
7-preclinical
Green fluorescent protein as a tracer in chimeric tissues: the power of vapor fixation.
PMID 18287644·Methods Mol Biol·2007
7-preclinical
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
PMID 17947484·Clin Cancer Res·2007
3-trial
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.
PMID 17721511·Nat Biotechnol·2007
8-other
Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detection.
PMID 17704782·Nat Methods·2007
8-other
Proton conductivity study of a fuel cell membrane with nanoscale resolution.
PMID 17274094·Chemphyschem·2007
8-other
Beta cells occur naturally in extrahepatic bile ducts of mice.
PMID 17179205·J Cell Sci·2007
4-observational
Gbx2 and Otx2 interact with the WD40 domain of Groucho/Tle corepressors.
PMID 17060451·Mol Cell Biol·2007
7-preclinical
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
PMID 16896006·J Clin Oncol·2006
3-trial
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
PMID 15956649·J Natl Cancer Inst·2005
3-trial
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
PMID 16361555·Clin Cancer Res·2005
8-other
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
PMID 15753462·J Clin Oncol·2005
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
105 E POPLAR AVE
CARRBORO, NC 27510

Location

Practice Location

105 E POPLAR AVE, CARRBORO, NC
(919) 928-4087

Quick Facts

NPI
1497118608
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
2
Locations
1
Publications
20

Are you this provider?

Claim Your Profile